Abbott Has Raised Its Dividend for 54 Years. These 3 Healthcare Stocks Keep Paying More
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Healthcare demand holds up in most economies. People still need glucose monitors, pacemakers, and health coverage during a downturn, so the cash flows behind these dividends tend to be firmer than the economy itself. That makes the sector useful for retirees who want income that keeps growing. All three companies below raised their payouts in 2026. The longest run belongs to Abbott Laboratories (NYSE:ABT | ABT Price Prediction), which in July declared its 410th consecutive quarterly dividend[1] during its 54th consecutive year of dividend increases. All three carry moderate yields, so the case rests on dividend growth the businesses can comfortably pay for.
Abbott Laboratories: A 54-Year Raise Streak Meets Tighter GAAP Coverage
Abbott pays $0.63 per share each quarter, or $2.52 per share a year. That works out to a 2.41% yield on a $103.31 stock price. The quarterly payout rose from $0.59 in 2025 to $0.63 in 2026, up about 6.8%. In 2016, the quarterly dividend was $0.26 per share. Abbott is an S&P 500 Dividend Aristocrat[1].
Dividend safety: GAAP earnings make coverage look tight this year. Trailing diluted EPS is $2.68, so the dividend uses about 94% of reported profit. Most of that pressure comes from deal accounting. Abbott closed the $21B Exact Sciences acquisition[2] on March 23, 2026. In its July report, management raised full-year adjusted EPS guidance to $5.45-$5.60[1]. Measured against the low end of that July range, the dividend takes about 46% of adjusted earnings. Abbott returned $2.1B[1] to shareholders via dividends and buybacks in the second quarter. Interest expense on the debt used to fund the acquisition has surged, leaving the company more leveraged than a year ago.
Bull case: Second-quarter revenue rose 13.0%[1] to $12.59B. Medical Devices grew 9.0%[1], and Diagnostics jumped 42.3% once Exact Sciences was added. The shares are down 15.77% year to date and trade at about 18x forward earnings. Analysts have a $119.60 price target, and 23 of 28 rate the stock a buy or strong buy. For an Aristocrat, that drop puts the stock well below where it started the year.
Risk: Competition in continuous glucose monitors is intensifying. CGM sales still rose 10.5%[1] to $2.19B in the second quarter, down from 13.8%[2] growth in the first. If that keeps slowing down, Abbott loses its main growth engine while Nutrition is already contracting (-3.1%[1]).
Medtronic: Highest Yield of the Three and Improving Cash Coverage
Medtronic (NYSE:MDT) yields 2.83%, the most of the three, with shares at $100.07. The quarterly dividend went from $0.71 to $0.72 in June 2026, about a 1.4% raise. That brings the annualized payout to $2.88 per share. The increase marked Medtronic’s 49th consecutive year of dividend increases[3], and the company’s dividend records go back to 1999.
Dividend safety: Free cash flow reached $1.29B[4] in fiscal Q1 2027, up 120.9%, while dividends paid came to $921M. The dividend takes roughly 71% of free cash flow. On GAAP earnings, the payout is about 71%. Against the low end of the $5.94-$6.00[4] non-GAAP EPS guidance from the fiscal Q1 report, it falls to about 48%. The CFO said the company has “a strong balance sheet,” and cash conversion is on a “strong path to getting to 80%,” up from 70%.
Bull case: Cardiac Ablation Solutions grew 88%[4], and the Cardiovascular Portfolio grew 18.9% organically. Management now expects fiscal 2027 organic revenue growth of 7.25% to 7.75%[4]. The company recently won FDA clearance that opens more procedures to its surgical robot (Barron’s). Planned separation of the Diabetes business should add about 100 basis points[5] to operating margin. The stock trades at about 17x forward earnings.
Risk: Medtronic still has to prove it can keep up with faster growth. Constant-currency non-GAAP EPS fell 2.0% in fiscal 2026, and the share price is up just 0.03% over five years. The latest quarter also included an extra selling week worth about $570 million[5], which flatters the headline growth. A raise of about 1.4% shows how carefully the board is managing the dividend.
Cigna Group: The Most Payout Cushion at About 8x Forward Earnings
Cigna Group (NYSE:CI) yields 2.27% at $271.51. Its quarterly payout rose from $1.51 to $1.56 in 2026, about a 3.3% raise, for a forward rate of $6.24 per share. Cigna’s dividend record is short. It paid a token $0.04 a year from 2008 through 2020, then changed to $1.00 quarterly in 2021. The payout has gone up every year since then. The next dividend has an ex-date of December 3, 2026, and will be paid on December 17.
Dividend safety: Cigna has the most cushion of the three. The dividend uses about 20% of the raised 2026 adjusted EPS outlook of at least $30.60, and about 27% of trailing GAAP EPS. Operating cash flow was $2.6 billion[6] in the third quarter. Debt-to-capital fell to 41.8%[6], close to the company’s 40% year-end target. Management also expects roughly $50B of total operating cash flow through 2030.
Bull case: Third-quarter adjusted EPS of $7.98 beat the $7.51 consensus, making five straight quarterly beats. The company aims for 10%-14% annual adjusted EPS growth and at least $45[6] in adjusted EPS by 2030. Despite that, the shares fell 11% over the past month and trade at about 8x forward earnings. Analysts’ target is $344.40.
Risk: Medical costs and regulation are the main threats. Cost trends were “continue to be elevated”[6], according to the CEO, and the medical care ratio hit 85%. Pretax adjusted income in Pharmacy Benefit Services fell 22%, and management expects industry rebate pools to shrink in 2027. Pharmacy benefit managers are also a frequent target for regulators.
How These Three Payers Fit Together
Abbott brings the longest raise run, Medtronic the highest yield, and Cigna the most room under its payout. Each raised its dividend in 2026 while paying out far more than it earns on an adjusted basis, and all three trade below their 52-week highs. That mix spreads dividend growth across medical devices and health coverage.
Contact [email protected] for any questions or corrections.







